Innovation Pharmaceuticals Inc
Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agree… Read more
Innovation Pharmaceuticals Inc (IPIX) - Net Assets
Latest net assets as of September 2023: $1.16 Million USD
Based on the latest financial reports, Innovation Pharmaceuticals Inc (IPIX) has net assets worth $1.16 Million USD as of September 2023.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($6.67 Million) and total liabilities ($5.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.16 Million |
| % of Total Assets | 17.43% |
| Annual Growth Rate | 34.09% |
| 5-Year Change | N/A |
| 10-Year Change | 69.07% |
| Growth Volatility | 783.08 |
Innovation Pharmaceuticals Inc - Net Assets Trend (2007–2023)
This chart illustrates how Innovation Pharmaceuticals Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Innovation Pharmaceuticals Inc (2007–2023)
The table below shows the annual net assets of Innovation Pharmaceuticals Inc from 2007 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-06-30 | $2.04 Million | -56.89% |
| 2022-06-30 | $4.73 Million | -37.01% |
| 2021-06-30 | $7.51 Million | +413.61% |
| 2020-06-30 | $1.46 Million | +135.41% |
| 2019-06-30 | $-4.13 Million | -91.96% |
| 2018-06-30 | $-2.15 Million | -46.93% |
| 2017-06-30 | $-1.46 Million | -149.39% |
| 2016-06-30 | $2.96 Million | -57.80% |
| 2015-06-30 | $7.02 Million | +482.42% |
| 2014-06-30 | $1.21 Million | +123.33% |
| 2013-06-30 | $-5.17 Million | +32.20% |
| 2012-06-30 | $-7.63 Million | -4.64% |
| 2011-06-30 | $-7.29 Million | -51.91% |
| 2010-06-30 | $-4.80 Million | -167.57% |
| 2009-06-30 | $-1.79 Million | -395.33% |
| 2008-06-30 | $-361.99K | -2038.68% |
| 2007-06-30 | $18.67K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Innovation Pharmaceuticals Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 12529087800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2023)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $52.00K | 2.55% |
| Other Comprehensive Income | $-5.00K | -0.25% |
| Other Components | $127.32 Million | 6244.09% |
| Total Equity | $2.04 Million | 100.00% |
Innovation Pharmaceuticals Inc Competitors by Market Cap
The table below lists competitors of Innovation Pharmaceuticals Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
DENTSPLY INTL
MU:DY2
|
$102.83K |
|
HOSTMORE LTD GB -20
F:9UX
|
$102.87K |
|
NISSHIN SEIFUN GRP
DU:NFR
|
$103.04K |
|
Raontec Inc.
KO:232680
|
$103.14K |
|
Jura Energy Corporation
PINK:JECFF
|
$102.80K |
|
Unibet Group plc
STU:UNBA
|
$102.77K |
|
PRIO3F
SA:PRIO3F
|
$102.75K |
|
PRIMARIS REIT A
F:H0D
|
$102.66K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Innovation Pharmaceuticals Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 4,730,000 to 2,039,000, a change of -2,691,000 (-56.9%).
- Net loss of 3,168,000 reduced equity.
- Dividend payments of 86,000 reduced retained earnings.
- Other comprehensive income decreased equity by 5,000.
- Other factors increased equity by 568,000.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-3.17 Million | -155.37% |
| Dividends Paid | $86.00K | -4.22% |
| Other Comprehensive Income | $-5.00K | -0.25% |
| Other Changes | $568.00K | +27.86% |
| Total Change | $- | -56.89% |
Book Value vs Market Value Analysis
This analysis compares Innovation Pharmaceuticals Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.05x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-06-30 | $0.00 | $0.00 | x |
| 2007-06-30 | $0.00 | $0.00 | x |
| 2008-06-30 | $-0.01 | $0.00 | x |
| 2009-06-30 | $-0.02 | $0.00 | x |
| 2010-06-30 | $-0.05 | $0.00 | x |
| 2011-06-30 | $-0.08 | $0.00 | x |
| 2012-06-30 | $-0.08 | $0.00 | x |
| 2013-06-30 | $-0.05 | $0.00 | x |
| 2014-06-30 | $0.01 | $0.00 | x |
| 2015-06-30 | $0.06 | $0.00 | x |
| 2016-06-30 | $0.02 | $0.00 | x |
| 2017-06-30 | $-0.01 | $0.00 | x |
| 2018-06-30 | $-0.01 | $0.00 | x |
| 2019-06-30 | $-0.02 | $0.00 | x |
| 2020-06-30 | $0.01 | $0.00 | x |
| 2021-06-30 | $0.02 | $0.00 | x |
| 2022-06-30 | $0.01 | $0.00 | x |
| 2023-06-30 | $0.00 | $0.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Innovation Pharmaceuticals Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -155.37%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -17600.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 3.69x
- Recent ROE (-155.37%) is below the historical average (-148.07%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -164.38% | 0.00% | 0.00x | 1.00x | $-36.20K |
| 2007 | -252.58% | 0.00% | 0.00x | 1.24x | $-49.03K |
| 2008 | 0.00% | 0.00% | 0.00x | 0.00x | $-473.99K |
| 2009 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.31 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.95 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.21 Million |
| 2012 | 0.00% | -667.32% | 26.17x | 0.00x | $-4.13 Million |
| 2013 | 0.00% | 0.00% | 0.00x | 0.00x | $-2.71 Million |
| 2014 | -683.83% | 0.00% | 0.00x | 9.00x | $-8.37 Million |
| 2015 | -187.14% | 0.00% | 0.00x | 2.04x | $-13.85 Million |
| 2016 | -433.60% | 0.00% | 0.00x | 3.86x | $-13.15 Million |
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | $-15.39 Million |
| 2018 | 0.00% | 0.00% | 0.00x | 0.00x | $-16.15 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-8.66 Million |
| 2020 | -454.72% | -1571.63% | 0.05x | 6.33x | $-6.79 Million |
| 2021 | -184.74% | -60313.04% | 0.00x | 1.90x | $-14.62 Million |
| 2022 | -148.86% | -39116.67% | 0.00x | 2.19x | $-7.51 Million |
| 2023 | -155.37% | -17600.00% | 0.00x | 3.69x | $-3.37 Million |
Industry Comparison
This section compares Innovation Pharmaceuticals Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Innovation Pharmaceuticals Inc (IPIX) | $1.16 Million | -164.38% | 4.74x | $102.82K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |